Cwm LLC trimmed its holdings in shares of Genmab A/S (NASDAQ:GMAB – Get Rating) by 15.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,032 shares of the company’s stock after selling 1,646 shares during the period. Cwm LLC’s holdings in Genmab A/S were worth $290,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. International Biotechnology Trust PLC bought a new stake in shares of Genmab A/S during the second quarter worth approximately $57,000. Captrust Financial Advisors raised its stake in shares of Genmab A/S by 62.0% during the first quarter. Captrust Financial Advisors now owns 2,658 shares of the company’s stock worth $96,000 after buying an additional 1,017 shares during the last quarter. Private Capital Group LLC raised its stake in shares of Genmab A/S by 14.1% during the second quarter. Private Capital Group LLC now owns 2,677 shares of the company’s stock worth $87,000 after buying an additional 331 shares during the last quarter. Wipfli Financial Advisors LLC bought a new stake in shares of Genmab A/S during the third quarter worth approximately $171,000. Finally, Sequoia Financial Advisors LLC raised its stake in shares of Genmab A/S by 51.9% during the first quarter. Sequoia Financial Advisors LLC now owns 8,738 shares of the company’s stock worth $316,000 after buying an additional 2,985 shares during the last quarter. 6.73% of the stock is owned by institutional investors.
Analysts Set New Price Targets
A number of equities research analysts recently weighed in on the stock. Citigroup downgraded shares of Genmab A/S from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 20th. SVB Leerink upped their target price on shares of Genmab A/S to $33.00 and gave the company a “market perform” rating in a research note on Thursday, November 10th. JPMorgan Chase & Co. upped their target price on shares of Genmab A/S from 3,450.00 to 3,600.00 and gave the company an “overweight” rating in a research note on Tuesday, January 3rd. AlphaValue raised shares of Genmab A/S to a “reduce” rating in a research note on Thursday, November 17th. Finally, DNB Markets downgraded shares of Genmab A/S from a “buy” rating to a “hold” rating in a research note on Monday, October 17th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $632.12.
Genmab A/S Stock Up 0.4 %
Genmab A/S (NASDAQ:GMAB – Get Rating) last announced its earnings results on Wednesday, November 9th. The company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.23 by $0.30. Genmab A/S had a net margin of 46.32% and a return on equity of 22.78%. The business had revenue of $553.71 million during the quarter, compared to analysts’ expectations of $486.10 million. On average, equities analysts expect that Genmab A/S will post 1.39 EPS for the current year.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
- Get a free copy of the StockNews.com research report on Genmab A/S (GMAB)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here’s Why
- Carvana Stock Rally, Here’s What You Need to Know
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.